Preparation and Evaluation of Silymarin beta-cyclodextrin Molecular Inclusion Complexes

被引:94
作者
Ghosh, A. [1 ]
Biswas, S. [1 ]
Ghosh, T. [1 ]
机构
[1] Himalayan Pharm Inst, Dept Pharmaceut, Rangpo, Sikkim, India
关键词
Bioava lability; inclusion complexes; silymarin; beta-cyclodextrin;
D O I
10.4103/0975-1483.83759
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Silymarin is a hepatoprotective agent, having poor water solubility and oral absorption of about 23 47%, leading to low bioavailability of the drug. The aim of the present study is to improve the solubility and dissolution rate and in turn the hepatoprotective activity of the drug, by formulating its inclusion complex with beta ((3)-cyclodextrin, using different methods. The phase solubility analysis indicates the formation of 1:1 molar inclusion complex of the drug with beta cyclodextrin. Apparent stability constant for Silymarin (K) was 722 K-1 with beta-cyclodextrin complex. The inclusion complexes were prepared by four different methods, namely, physical mixing, kneading, co-precipitation, and solvent evaporation. The prepared complexes were characterized using differential scanning colorimetry, scanning electron microscopy, and x-ray diffractometry. The inclusion complex prepared by the co-precipitation methods exhibits an overall best result, with respect to the formulation of sustained release formulations.
引用
收藏
页码:205 / 210
页数:6
相关论文
共 18 条
[1]   Study of omeprazole-γ-cyclodextrin complexation in the solid state [J].
Arias, MJ ;
Moyano, JR ;
Muñoz, P ;
Ginés, JM ;
Justo, A ;
Giordano, F .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2000, 26 (03) :253-259
[2]  
Attma AA, 2004, J PHARM RES, V3, P47
[3]   Improvement of the in vitro dissolution of praziquantel by complexation with α-, β- and γ-cyclodextrins [J].
Becket, G ;
Schep, LJ ;
Tan, MY .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 179 (01) :65-71
[4]   CYCLODEXTRINS IN THE PHARMACEUTICAL FIELD [J].
BEKERS, O ;
UIJTENDAAL, EV ;
BEIJNEN, JH ;
BULT, A ;
UNDERBERG, WJM .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1991, 17 (11) :1503-1549
[5]  
Deshmukh S. S., 2007, INDIAN DRUGS, V44, P677
[6]  
Kamal D, 2007, CURR DRUG DELIV, V4, P21
[7]  
Loffsson T, 1996, J PHARM SCI, V85, P1017
[8]  
Loftsson T, 2004, AM J DRUG DELIV, V2, P1
[9]  
Luper S, 1998, Altern Med Rev, V3, P410
[10]   Solid dispersion of hydroxypropyl β-cyclodextrin and ketorolac:: Enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats [J].
Nagarsenker, MS ;
Meshram, RN ;
Ramprakash, G .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2000, 52 (08) :949-956